Repligen(RGEN)

Focus: Repligen is a mid-cap biotech company headquartered in Waltham, MA with 1,001-5,000 employees, operating as a public company (RGEN) in the broader pharmaceutical/biotech segment.

Profile data last refreshed 12h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Repligen

AI assessmentNot Hiring

No open roles listed right now. Follow Repligen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$632M

Pipeline & Clinical Trials

Secretin Synthetic Human

Pancreas Cancer

Phase 1

Clinical Trials (1)

NCT01371240Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity

Phase 1

Help build intelligence for Repligen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong cash position of $757M provides financial stability and runway for pipeline advancement without near-term restructuring pressure
Diversified pipeline across 9 active programs spanning psychiatry (bipolar depression, OCD), neurology (autism, MS), and rare diseases (mitochondrial disease, pancreatitis)
Active hiring in Engineering (5 roles) signals product/platform development investment and potential for technical career growth

Watch Out For

Revenue declined 21% YoY ($802M to $632M) with net income dropping 81% ($186M to $36M), suggesting operational headwinds or one-time charges requiring clarification
Minimal R&D spend ($43M, 7% of revenue) is unusually low for a biotech, indicating limited internal discovery capacity or heavy reliance on external partnerships

Generated by Claude from Repligen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RG2077

Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT00076934Safety of RG2077 in Patients With Multiple Sclerosis

Phase 1

RG2133

Mitochondrial Diseases

Phase 1

Clinical Trials (1)

NCT00060515RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Phase 1

RG2417

Bipolar I Depression

Phase 2

Clinical Trials (1)

NCT00812058A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Phase 2

RG1068

Obsessive Compulsive Disorder (OCD)

Phase 2

Clinical Trials (1)

NCT00216294Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

Phase 2

Subcutaneous Secretin

Schizophrenia

Phase 2

Clinical Trials (1)

NCT00235274Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

Phase 2

Uridine

Bipolar Depression

Phase 2

Clinical Trials (1)

NCT00322764Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

Phase 2

RG1068

Autism

Phase 3

Clinical Trials (1)

NCT00036231Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

Phase 3

RG1068

Pancreatitis

Phase 3

Clinical Trials (1)

NCT00660335Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

Phase 3

RG1068

Autism

Phase 3

Clinical Trials (1)

NCT00036244Synthetic Human Secretin in Children With Autism

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Neurology, Gastroenterology, Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

4 pipeline

Gastroenterology

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$632M21%

R&D Spend

$43M(7%)3%

Net Income

$36M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles